Early Improvement in Marrow Fibrosis Following Haploidentical Stem Cell Transplantation for a Patient with Myelodysplastic Syndrome with Bone Marrow Fibrosis

Overview

Journal Intern Med

Specialty General Medicine

Date 2016 Nov 18

PMID 27853082

Authors

Shuichiro Takahashi

Riko Tsumanuma

Keiko Aizawa

Mitsumasa Osakabe

Kunihiko Maeda

Ejiro Omoto

Affiliations

Soon will be listed here.

Abstract

The prognosis for myelodysplastic syndrome with bone marrow fibrosis (MDS-F) is worse than the prognosis of MDS without fibrosis. Hematopoietic stem cell transplantation (HSCT) is the only curative therapy; however, the indications and the procedures involved in HSCT remain unclear. We herein describe a 69-year-old Japanese man with MDS-F who received haploidentical HSCT and post-transplantation cyclophosphamide. Although the first HSCT resulted in secondary graft failure, the second HSCT using PTCy led to successful engraftment after early improvement in fibrosis. Since the incidence of graft failure is high in myelofibrosis patients, a secondary HSCT using PTCy may be successful if employed.

References

Kroger N, Zabelina T, van Biezen A, Brand R, Niederwieser D, Martino R . Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis. Haematologica. 2010; 96(2):291-7. PMC: 3031698. DOI: 10.3324/haematol.2010.031229. View

Yoshihara S, Ikegame K, Taniguchi K, Kaida K, Kim E, Nakata J . Salvage haploidentical transplantation for graft failure using reduced-intensity conditioning. Bone Marrow Transplant. 2011; 47(3):369-73. DOI: 10.1038/bmt.2011.84. View

Kerbauy D, Gooley T, Sale G, Flowers M, Doney K, Georges G . Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant. 2007; 13(3):355-65. DOI: 10.1016/j.bbmt.2006.11.004. View

Lambertenghi-Deliliers G, Orazi A, Luksch R, Annaloro C, Soligo D . Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinico-pathological entity. Br J Haematol. 1991; 78(2):161-6. DOI: 10.1111/j.1365-2141.1991.tb04411.x. View

Takagi S, Ota Y, Uchida N, Takahashi K, Ishiwata K, Tsuji M . Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis. Blood. 2010; 116(4):649-52. DOI: 10.1182/blood-2009-11-252601. View

Raiola A, Dominietto A, Ghiso A, di Grazia C, Lamparelli T, Gualandi F . Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant. 2012; 19(1):117-22. DOI: 10.1016/j.bbmt.2012.08.014. View

Thiele J, Kvasnicka H, Facchetti F, Franco V, van der Walt J, Orazi A . European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005; 90(8):1128-32. View

Devine S, Hoffman R, Verma A, Shah R, Bradlow B, Stock W . Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood. 2002; 99(6):2255-8. DOI: 10.1182/blood.v99.6.2255. View

Sale G, Deeg H, Porter B . Regression of myelofibrosis and osteosclerosis following hematopoietic cell transplantation assessed by magnetic resonance imaging and histologic grading. Biol Blood Marrow Transplant. 2006; 12(12):1285-94. DOI: 10.1016/j.bbmt.2006.07.008. View

10.

Filipovich A, Weisdorf D, Pavletic S, Socie G, Wingard J, Lee S . National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005; 11(12):945-56. DOI: 10.1016/j.bbmt.2005.09.004. View

11.

Della Porta M, Malcovati L . Myelodysplastic syndromes with bone marrow fibrosis. Haematologica. 2011; 96(2):180-3. PMC: 3031682. DOI: 10.3324/haematol.2010.039875. View

12.

Greenberg P, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F . Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120(12):2454-65. PMC: 4425443. DOI: 10.1182/blood-2012-03-420489. View

13.

Brunstein C, Fuchs E, Carter S, Karanes C, Costa L, Wu J . Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011; 118(2):282-8. PMC: 3138683. DOI: 10.1182/blood-2011-03-344853. View

14.

Verhoef G, De Wolf-Peeters C, Ferrant A, Deprez S, Meeus P, Stul M . Myelodysplastic syndromes with bone marrow fibrosis: a myelodysplastic disorder with proliferative features. Ann Hematol. 1991; 63(5):235-41. DOI: 10.1007/BF01698371. View

15.

Ballen K . How to manage the transplant question in myelofibrosis. Blood Cancer J. 2012; 2(3):e59. PMC: 3317522. DOI: 10.1038/bcj.2012.3. View

16.

Ballen K, Shrestha S, Sobocinski K, Zhang M, Bashey A, Bolwell B . Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant. 2009; 16(3):358-67. PMC: 2908949. DOI: 10.1016/j.bbmt.2009.10.025. View

17.

Brodsky R, Luznik L, Bolanos-Meade J, Leffell M, Jones R, Fuchs E . Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplant. 2008; 42(8):523-7. PMC: 3086163. DOI: 10.1038/bmt.2008.203. View

18.

Udomsakdi-Auewarakul C, Visuthisakchai S, Sangruchi T, Issaragrisil S . Reversal of marrow fibrosis in agnogenic myeloid metaplasia by allogeneic peripheral blood stem cell transplantation. Asian Pac J Allergy Immunol. 2003; 21(2):121-6. View

19.

Tefferi A . Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol. 2005; 23(33):8520-30. DOI: 10.1200/JCO.2004.00.9316. View

20.

Scott B, Storer B, Greene J, Hackman R, Appelbaum F, Deeg H . Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia. Biol Blood Marrow Transplant. 2007; 13(3):345-54. DOI: 10.1016/j.bbmt.2006.10.030. View